AstraZeneca announces Stage III study outcomes of naloxegol in individuals with non-cancer pain AstraZeneca today announced the outcomes of a Stage III long-term protection and tolerability research of the once-daily 25mg dosage of naloxegol, in individuals with non-cancer discomfort and opioid-induced constipation pharmacy news . Naloxegol can be an investigational peripherally-performing mu-opioid receptor antagonist , which includes been studied in OIC in adult sufferers with chronic non-cancer discomfort, a common condition due to prescription opioid pain medications. Data were provided at the American University of Gastroenterology 2013 Annual Scientific Getting together with in NORTH PARK, California. The Stage III study, KODIAC-08s selection of a preexisting laxative treatment program for OIC.
More information about the FALCON medical trial is available at and searching beneath the term FALCON. ‘Despite advancements in treatment and recognition, breast cancer remains the best reason behind cancer death in females around the global globe,’ stated Yuri Rukazenkov, MD, Medical Research Director, AstraZeneca. ‘The FALCON trial is section of AstraZeneca's dedication to the continued research and evaluation of treatment plans for metastatic breast malignancy, and optimizing and developing breasts cancers therapies for all individual groups.’..